Sign in
WithdrawnNo phase

Circulating Tumor DNA to Monitor the Efficacy of Total Neoadjuvant Therapy for Rectal Cancer

Key facts

Who runs it
Case Comprehensive Cancer Center
Where
Cleveland, United StatesSee the site
Trial code
Status
Withdrawn
Started
30 Dec 2023
Ended
30 Jun 2024
Type of study
Observational
Treatments tested
  • SignateraTM assay
Record updated
12 April 2024
Why it stopped
Sponsor already published research that was to be obtained from this study.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Newly histologically documented rectal adenocarcinoma or biopsy-proven adenoma with MRI rectum and CT chest/abdomen or PET/CT imaging consistent with stage II or III disease
  • Plan is for participant to undergo standard TNT with induction chemoradiation
  • Age ≥ 18 years of age

Who cannot take part

  • Received prior therapy for this rectal cancer
  • Stage I, recurrent, or metastatic rectal cancer
  • No baseline tumor biopsies with adenocarcinoma or adequate amount of tissue from biopsies available to send for SignateraTM assay development

Where in United States

  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer CenterCleveland, United States

About the trial

What the trial wants to find out

The purpose of this study is to use the SignateraTm assay created from rectal tumor biopsies to monitor participants' blood for fragments of DNA shed by tumor cells. The tumor DNA fragments are referred to as circulating tumor DNA, or ctDNA for short.

Treatments tested

  • SignateraTM assay

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
12 April 2024